TCGA-E2-A15A-06A-11R-A12D-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- G2M_CHECKPOINT+0.480
- MYC_TARGETS_V1+0.450
- ALLOGRAFT_REJECTION+0.440
- MYC_TARGETS_V2+0.350
- MITOTIC_SPINDLE+0.320
- PROTEIN_SECRETION+0.310
- PI3K_AKT_MTOR_SIGNALING+0.290
- MTORC1_SIGNALING+0.230
- INTERFERON_GAMMA_RESPONSE+0.210
Top 10 suppressed
- HYPOXIA-0.360
- HEDGEHOG_SIGNALING-0.340
- CHOLESTEROL_HOMEOSTASIS-0.310
- KRAS_SIGNALING_DN-0.300
- MYOGENESIS-0.300
- COAGULATION-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- GLYCOLYSIS-0.230
- UV_RESPONSE_DN-0.230
- PANCREAS_BETA_CELLS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518289 | — | E | 0.802 |
| 2 | C3N-00203 | — | cohortA1 | 0.797 |
| 3 | MDT-AP-3042 | Med | Medulloblastoma | 0.790 |
| 4 | KG1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.789 |
| 5 | TCGA-18-3410-01A-01R-0980-07 | — | cohortSQ1 | 0.787 |
| 6 | MNG1170 | — | — | 0.785 |
| 7 | MBCProject_1852_T1_RNA | — | B | 0.785 |
| 8 | TCGA-DK-A1A6-01A-11R-A13Y-07 | — | — | 0.784 |
| 9 | MNG826 | — | — | 0.782 |
| 10 | 58c2404d-b213-4a7f-a8fc-11081a88091b | — | — | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.030 | Inavolisib | — uncovered |